Similar articles

• Everolimus and mTOR inhibitors in liver transplantation: opening the "box".

  Everson GT. Everson GT. Liver Transpl. 2006 Nov;12(11):1571-3. doi: 10.1002/lt.20845. Liver Transpl. 2006. PMID: 17058246 Review. No abstract available.
• Sirolimus to replace calcineurin inhibitors? Too early yet.

  Cravedi P, Ruggenenti P, Remuzzi G. Cravedi P, et al. Lancet. 2009 Apr 11;373(9671):1235-6. doi: 10.1016/S0140-6736(09)60709-1. Lancet. 2009. PMID: 19362662 Review. No abstract available.
• Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.

  Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H. Zuckermann A, et al. J Heart Lung Transplant. 2008 Feb;27(2):141-9. doi: 10.1016/j.healun.2007.08.014. J Heart Lung Transplant. 2008. PMID: 18267219 Review.
• Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.

  Rothenburger M, Zuckermann A, Bara C, Hummel M, Strüber M, Hirt S, Lehmkuhl H; Certican Consensus Study Group. Rothenburger M, et al. J Heart Lung Transplant. 2007 Apr;26(4):305-11. doi: 10.1016/j.healun.2007.01.010. J Heart Lung Transplant. 2007. PMID: 17403469
• Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.

  Cowan PA, Heizer KE. Cowan PA, et al. Nephrol Nurs J. 2000 Dec;27(6):623-5. Nephrol Nurs J. 2000. PMID: 16649344 Review.